EN DE

ASIA VETS HOLDINGS LTD. (5RE) Fair Value & Analysis

Healthcare · SG · Market cap 11.0M SGD

AV ASIA VETS HOLDINGS LTD. 5RE · SG
Price0.0780 SGD
Fair Value0.0640 SGD
Upside-18.0%
Quality53/100
Watch ASIA VETS HOLDINGS LTD. for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Low debt · generates free cash flow
Trails peers (3/11)
Narrow moat 0/100
Evidence: Medium Range 0.0640 SGD – 0.0640 SGD Share as image

Fair value as of: Aug 13, 2026

From 9 valuation models · updated 4 days ago

Share price +20.0% over the past month.

A solid business, but screening 18% overvalued on our models.

Fair value for all 35,000+ stocks, review alerts and the diversification check: 14 days of Pro free, no card.

What matters now

  • The price sits above even our optimistic bull case (0.0640 SGD). The favourable scenario is already priced in.
  • Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

0.1050 SGD 0.0210 SGD Fair Value 0.0640 SGD Apr 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 0.0210 SGD – 0.1050 SGD · the 0.0780 SGD price screens above the 0.0640 SGD fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

ASIA VETS HOLDINGS LTD. (5RE) currently trades at 0.0780 SGD, while our model-based Fair Value estimate is 0.0640 SGD, implying the stock looks roughly 18.0% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Trailing-twelve-month revenue stands at 2.3M SGD. Revenue grew 0.6% year over year. It earns a return on equity of -51.2%. Fundamentals as of Aug 13, 2026

The share trades about 35% below its 52-week high and 271% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -18%, 5RE screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 0.0600 SGD 0.0600 SGD 0.0600 SGD 80
Rev-Margin DCF 0.0600 SGD 0.0600 SGD 0.0600 SGD 74
Gordon GGM 0.0100 SGD 0.0100 SGD 0.0200 SGD 70
All 9 models by family
DCF Models
FCF DCF 0.0600 SGD 0.0600 SGD 0.0600 SGD 38
5Y Revenue Exit 0.0600 SGD 0.0600 SGD 0.0600 SGD 39
10Y Revenue Exit 0.0600 SGD 0.0600 SGD 0.0600 SGD 36
Dividend Discount
Gordon GGM 0.0100 SGD 0.0100 SGD 0.0200 SGD 70
DDM Multi-Stage 0.0100 SGD 0.0200 SGD 0.0200 SGD 61
Multiples
EV/Revenue 0.0600 SGD 0.0600 SGD 0.0600 SGD 43
Asset-Based
NCAV (Graham) 0.0300 SGD 0.0400 SGD 0.0600 SGD 50
Growth DCF
Growth DCF 0.0600 SGD 0.0600 SGD 0.0600 SGD 80
Rev-Margin DCF 0.0600 SGD 0.0600 SGD 0.0600 SGD 74

Widest divergence: DCF Models (0.0600 SGD) versus Dividend Discount (0.0100 SGD). Highest evidence: Growth DCF (80).

Notify me when 5RE reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 2.3M SGD
Revenue growth (YoY) +0.6%
Net margin -279%
Return on equity -51.2%
Free cash flow 72.2K SGD FY2025
Operating margin -39.6%
More key figures
EPS (TTM) -0.0400 SGD
EPS growth (YoY) -52.3%

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 53/100

Of which business quality 56 · Market factors (momentum, volatility) 64

Profitability 4
Margins and returns on capital today
Quality Growth 25
Are margins and returns improving?
Cashflow 46
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 33
Calm price path (market factor)
Momentum 77
Price trend over the last 3–12 months (market factor)
52W Momentum 79
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Asia Vets Holdings Ltd., through its subsidiary, AVH Animal Ark Pte. Ltd., provides veterinary care and clinical services to small animals in Singapore.

Full company description

Asia Vets Holdings Ltd., through its subsidiary, AVH Animal Ark Pte. Ltd., provides veterinary care and clinical services to small animals in Singapore. The company operates two veterinary clinics, which provides general veterinary services including medical, surgical, and dental care for small animals, such as dogs, cats, rabbits, hamsters, guinea pigs, and chinchillas. It also provides vaccination, health check, dentistry, acupuncture, and traditional Chinese medicines; and natural killer cell and stem cell therapies, in-house blood tests, such as biochemistry and hematology, interventional radiology and endoscopy, surgery and invasive procedures, and pet diet prescription services, as well as diagnostic imaging, which includes ultrasonography, digital radiography, laparoscopy, and endoscopy. Asia Vets Holdings Ltd. was formerly known as Smartflex Holdings Ltd. and changed its name to Asia Vets Holdings Ltd. in July 2018. The company was incorporated in 2010 and is headquartered in Singapore. Asia Vets Holdings Ltd. operates as a subsidiary of Tan Gee Beng Pte. Ltd.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

ASIA VETS HOLDINGS LTD. reported revenue of 2.3M SGD in FY2025 versus 3.1M SGD in FY2021, a compound −6.7%/yr. Reported net income was −6.5M SGD in FY2025.

Growth Quality 7/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
2.3M SGD
Latest YoY
−8.0%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−1.4%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−11.7%
Avg. growth/yr (12Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−17.4%
Revenue −6.7%/yr
FY21 3.1M SGD
FY22 2.4M SGD
FY23 2.3M SGD
FY24 2.5M SGD
FY25 2.3M SGD
Net income
FY21 −277K SGD
FY22 −767K SGD
FY23 −744K SGD
FY24 −2.0M SGD
FY25 −6.5M SGD

5RE screens 18% overvalued. Compare with HCA Healthcare, Inc →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "ASIA VETS HOLDINGS LTD. Fair Value". https://www.fairvalue-calculator.com/stock/5RE

Peer Group

Medical Care Facilities · 267 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 53 · Below median
Fair Value upside −23% · Below median
Return on assets -4% · Bottom 25%
Operating margin (TTM) -40% · Bottom 25%
Revenue growth 1% · Below median
Dividend yield (TTM) 2.7% · Above median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/B 0.91× · Cheaper than median
P/S (TTM) 3.70× · Pricier than 75% of peers
P/FCF 118.9× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 3 · sector 27
FUTURE 3 · sector 23
PAST 0 · sector 29
HEALTH 100 · sector 90
DIVIDEND 53 · sector 41

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Compare ASIA VETS HOLDINGS LTD. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is ASIA VETS HOLDINGS LTD. (5RE) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 0.0640 SGD versus a price of 0.0780 SGD, about −18% (overvalued).
What is the fair value of 5RE?
Our model-based fair value for ASIA VETS HOLDINGS LTD. is 0.0640 SGD (as of Aug 13, 2026), built from audited fundamentals. The current price is 0.0780 SGD.
What is the quality score of 5RE?
ASIA VETS HOLDINGS LTD. has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of ASIA VETS HOLDINGS LTD. (5RE)?
ASIA VETS HOLDINGS LTD. reported trailing-twelve-month revenue of about 2.3M SGD (latest available figure, as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track ASIA VETS HOLDINGS LTD. and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.